ABBVIE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1328
- Registration Number
- NCT05889182
- Locations
- ๐ญ๐บ
Duplicate_Obudai Egeszsegugyi Centrum Kft. /ID# 256366, Budapest, Hungary
๐บ๐ธCahaba Dermatology & Skin Health Center /ID# 254876, Birmingham, Alabama, United States
๐บ๐ธMedical Dermatology Specialists /ID# 254226, Phoenix, Arizona, United States
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT05878067
- Locations
- ๐บ๐ธ
Canyon City Eyecare /ID# 253652, Azusa, California, United States
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 523
- Registration Number
- NCT05861427
- Locations
- ๐ฏ๐ต
Konan Medical Center /ID# 245557, Kobe-shi, Hyogo, Japan
๐ฏ๐ตNishinomiya Municipal Central Hospital /ID# 246571, Nishinomiya-shi, Hyogo, Japan
๐ฏ๐ตYamaguchi Clinic /ID# 246370, Nishinomiya-shi, Hyogo, Japan
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT05843643
- Locations
- ๐จ๐ณ
People's Hospital of Xinjiang Uygur Autonomous Region /ID# 266897, Urumqi, Xinjiang, China
๐บ๐ธAZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona, United States
๐บ๐ธAZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 254767, Flagstaff, Arizona, United States
An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
- Conditions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT05841537
- Locations
- ๐ซ๐ท
CHU Montpellier - Hopital Saint Eloi /ID# 253096, Montpellier Cedex 5, Herault, France
๐ฎ๐นAzienda Ospedaliero Universitaria Careggi /ID# 265159, Florence, Firenze, Italy
๐ฎ๐นFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 263587, Milano, Italy
A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05836506
- Locations
- ๐บ๐ธ
Acpru /Id# 254926, Grayslake, Illinois, United States
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
- Conditions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 200
- Registration Number
- NCT05827887
- Locations
- ๐ฎ๐ฑ
Assuta Ashdod Medical Center /ID# 260020, Ashdod, HaDarom, Israel
๐ฎ๐ฑSoroka University Medical Center /ID# 254551, Be'er Sheva, HaDarom, Israel
๐ฎ๐ฑEdith Wolfson Medical Center /ID# 269740, Holon, HaMerkaz, Israel
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- ๐บ๐ธ
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
๐ฎ๐นIRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
๐บ๐ธArizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT05821855
- Locations
- ๐จ๐ณ
Qingdao Eye Hospital of Shandong First Medical University /ID# 243992, Qingdao, China
๐จ๐ณThe second affiliated hospital of Zhejiang University school of medicine /ID# 243996, Hangzhou, Zhejiang, China
๐จ๐ณPeking University Third Hospital /ID# 243994, Beijing, Beijing, China
A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT05818709
- Locations
- ๐ฉ๐ช
Dermatologische Gemeinschaftspraxis Mahlow /ID# 243805, Blankenfelde-Mahlow, Brandenburg, Germany
๐ช๐ธInstituto Medico Miramar /ID# 251640, Mรกlaga, Malaga, Spain
๐ฉ๐ชHautok and Hautok-cosmetics /ID# 243800, Muenchen, Germany